651eTiP CAPItana: A phase IIIb study to evaluate the use of capivasertib in combination with fulvestrant in patients with advanced breast cancer who have relapsed/progressed on endocrine therapy and CDK4/6 inhibitors reflecting real-world clinical practice in Spain NCT06764186Rodrigo Sánchez-Bayona, C. Saura Manich, T. Pascual et al.|Annals of Oncology|2025Cited by 0